Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

DOBROTKOVÁ Viera CHLAPEK Petr MAZÁNEK Pavel ŠTĚRBA Jaroslav VESELSKÁ Renata

Year of publication 2018
Type Article in Periodical
Magazine / Source BMC Cancer
MU Faculty or unit

Faculty of Science

Citation
Web https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5
Doi http://dx.doi.org/10.1186/s12885-018-4966-5
Keywords Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma
Description For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.